Seeking Alpha
11 Nov 2026, 20:38 UTC · 47m ago
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Impact · against what's priced in
The announcement of the March 2027 PDUFA date for zanzalintinib does not move the needle for EXEL, as the market has already priced in the successful phase 3 completion and pending regulatory approval of the drug.
- EXEL+0.00
Already priced in
- The price assumes
the successful phase 3 completion for zanzalintinib in metastatic colorectal cancer and its pending regulatory approval
The confirmation of a PDUFA date in early March 2027 for zanzalintinib directly supports an outcome the market already assumes is happening.
What EXEL's price assumes · Sep 4
Top 1 mover · tap to explore
